Related Experiment Videos
Everything Old Is New Again: Using Nelfinavir to Radiosensitize Rectal Cancer
Raymond E Meyn1, Sunil Krishnan2, Heath D Skinner3
1Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract:
Repurposing agents approved for other indications to radiosensitize tumors may be advantageous. The study by Hill and colleagues utilizes nelfinavir, an HIV protease inhibitor (PI), in combination with radiotherapy in rectal cancer in a prospective study. This combination may improve tumor perfusion and regression compared with radiotherapy alone.